ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1648

Lupus Anticoagulant At First Pregnancy Visit Is Predictive of Pregnancy Loss

Michelle Petri1, Anil Mankee2, Ehtisham Akhter2, Hong Fang1 and Laurence S. Magder3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: pregnancy and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Clinical Aspects/Pregnancy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Multiple factors, including proteinuria, antiphospholipid syndrome, thrombocytopenia and hypertension, are predictive of pregnancy loss in SLE. In the PROMISSE study of mediators of pregnancy loss, only a battery of lupus anticoagulant tests (Dil PT, dRVVT, PTT LA, and KCT) were predictive of adverse pregnancy outcomes (including pregnancy loss, preterm birth, pre-eclampsia, and small for gestational age). We examined the predictive value of one baseline lupus anticoagulant test (dRVVT) with pregnancy loss alone in women with SLE.

Methods: This analysis is based on pregnancies that were observed from 1987 to 2011.  After excluding twin pregnancies, there were 402 pregnancies from 326 different women.  We determined the percentage of women who had a pregnancy loss in groups defined by potential risk factors.  Generalized Estimating Equations were used to calculate p-values, accounting for repeated pregnancies of the same woman.

Results:

The age at pregnancy was <20 years (3%), 20-29 (50%), 30-39 (43%), and over 40 (3%). 59% were Caucasian and 34% African-American. Predictors of pregnancy loss are shown in the table. Lupus anticoagulant at the 1stvisit was highly predictive of pregnancy loss (and ever being positive was also associated, although less so).

Table 1: Proportion with Pregnancy Loss, by characteristics of the patients.

Patient Characteristic

Proportion (%) with miscarriage

P-value2

All

46/402 (11%)

 

Age

 

   <20

   20-29

   30-39

   40+

1/13 (8%)

20/202 (10%)

19/172 (11%)

6/12 (50%)

0.38

Ethnicity

 

    Caucasian

    African American

    Other

28/235 (12%)

14/135 (10%)

4/31 (13%)

0.77

Year of conception

 

    1986-1994

    1995-1999

    2000-2004

    2005+

14/115 (12%)

13/83 (16%)

10/80 (13%)

9/122 (7%)

0.32

RVVT measured in first trimester1

 

     Normal

     High (>45)

     No first-trimester measure  

16/187 (9%)

6/15 (40%)

24/200 (12%)

0.0022

Ever positive for high RVVT

 

    No

    Yes

    Unknown

26/278 (9%)

20/117 (17%)

0/7 (0%)

0.030

Anticardiolipin-IGG measured in first trimester1

 

    Normal

    High

    No first-trimester measure

11/127 (9%)

1/11 (9%)

34/264 (13%)

0.96

Anticardiolipin ever present

 

    No

    Yes

    Unknown

16/158 (10%)

30/241 (12%)

0/3 (0%)

0.41

Moderately active lupus

 

   No

   Yes

   Unknown

27/281 (10%)

7/27 (26%)

12/94 (13%)

0.012

Low Complement in first trimester

 

   No

   Yes

   Unknown

23/227 (10%)

11/78 (14%)

12/97 (12%)

0.37

Anti-dsDNA in first trimester

 

   No

   Yes

  Unknown

18/198 (9%)

15/104 (14%)

13/100 (13%)

0.18

Mean Prednisone dose in first trimester

 

    <10 mg

   10+

   Unknown

23/220 (10%)

11/88 (13%)

12/94 (13%)

0.60

1Based on the average of the measures during the first trimester or prior to miscarriage if miscarriage occurred in first trimester.

2Excludes the unknowns in the calculations.

 Conclusion: The strongest predictor of pregnancy loss in SLE is the lupus anticoagulant in the first trimester by dRVVT testing. In contrast to the PROMISSE study, 3 lupus anticoagulant assays were not necessary. In addition, moderate disease activity by the physician global assessment was also predictive of pregnancy loss, but not low complement, anti-dsDNA, or anticardiolipin. These data suggest that treatment of the lupus anticoagulant should be considered, even in the absence of prior history of miscarriage.


Disclosure:

M. Petri,
None;

A. Mankee,
None;

E. Akhter,
None;

H. Fang,
None;

L. S. Magder,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-anticoagulant-at-first-pregnancy-visit-is-predictive-of-pregnancy-loss/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology